SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Life sciences intellectual property licensing at the Massachusetts Institute of Technology
6 references·2 citing·33 second hop
Life sciences intellectual property licensing at the Massachusetts Institute of Technology (2021)Life sciences intellectual property licen…2016 FDA drug approvals (2017)2016 FDA drug approvalsAn Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011 (2013)An Improved Approach To Measu…The Role of Public-Sector Research in the Discovery of Drugs and Vaccines (2011)The Role of Public-Sector Res…Lessons from 60 years of pharmaceutical innovation (2009)Lessons from 60 years of phar…Macro trends in pharmaceutical innovation (2005)Macro trends in pharmaceutica…Inside the Triple Helix: Technology Transfer And Commercialization In The Life Sciences (2004)Inside the Triple Helix: Tech…Who counts as an inventor? Seniority and gender in 430,000 biomedical inventor–researcher teams (2023)Who counts as an inventor? Se…Systematic analysis of 50 years of Stanford University technology transfer and commercialization (2022)Systematic analysis of 50 yea…Product innovation, product-market competition and persistent profitability in the U.S. pharmaceutical industry (1999)Returns on Research and Development for 1990s New Drug Introductions (2002)Science and Engineering Indicators (2004)Old drugs – new uses (2007)How to Revive Breakthrough Innovation in the Pharmaceutical Industry (2011)The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance (2017)Academic research and industrial innovation (1991)The increasing linkage between U.S. technology and public science (1997)Is Technological Change In Medicine Worth It? (2001)History and health policy in the United States: putting the past back in (2007)The Idea Gap in Pink and Black (2010)Determinants and public policy implications of academic-industry knowledge transfer in life sciences: a review and a conceptual framework (2015)Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology (1996)The price of innovation: new estimates of drug development costs (2003)The black swan: the impact of the highly improbable (2007)The productivity crisis in pharmaceutical R&D (2011)THE WORLD MEDICINES SITUATION 2011 (2011)Drug discovery in pharmaceutical industry: productivity challenges and trends (2012)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 (2010)Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders (2014)Public sector financial support for late stage discovery of new drugs in the United States: cohort study (2019)Missing Novelty in Drug Development (2021)The importance of new companies for drug discovery: origins of a decade of new drugs (2010)US academic drug discovery (2011)The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs (2015)Recombinant Uncertainty in Technological Search (2001)Network Dynamics and Field Evolution: The Growth of Interorganizational Collaboration in the Life Sciences (2005)The Increasing Dominance of Teams in Production of Knowledge (2007)Patents, Citations, and Innovations (2002)Large teams develop and small teams disrupt science and technology (2019)Creativity in large pharmaceutical research organizations: unleash the hungry drug hunter (2017)A Changing Landscape in Cardiovascular Research Publication Output (2018)
this work references cited by second hop

References

  • 2009Lessons from 60 years of pharmaceutical innovation1,207 cited
  • 2011The Role of Public-Sector Research in the Discovery of Drugs and Vaccines245 cited
  • 2013An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011138 cited
  • 20172016 FDA drug approvals122 cited
  • 2005Macro trends in pharmaceutical innovation112 cited
  • 2004Inside the Triple Helix: Technology Transfer And Commercialization In The Life Sciences69 cited

Cited by

  • 2022Systematic analysis of 50 years of Stanford University technology transfer and commercialization13 cited
  • 2023Who counts as an inventor? Seniority and gender in 430,000 biomedical inventor–researcher teams6 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work